Low-intensity extracorporeal shock wave therapy (LI-SWT) did not improve erectile dysfunction compared to a sham procedure in radical prostatectomy patients. Fewer than 20% of men in the LI-SWT group ...
The ARID II trial investigates the Voro Urologic Scaffold's safety and efficacy in prostate cancer patients undergoing robotic-assisted radical prostatectomy. The scaffold aims to improve urinary ...
Up to 72% of patients with prostate cancer who undergo radical prostatectomy experience urinary incontinence in the first 3 months after surgery. Patients with postoperative urinary incontinence after ...
The use of antiplatelet and/or anticoagulant medications has increased due to irregular diets, limited physical activity, and ...
Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later ...
The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...
No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND). The extent of pelvic lymph node dissection (PLND) in patients undergoing radical prostatectomy (RP) for ...
A new study found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. Published in Nature Communications, a new study ...
Prostate-specific membrane antigen–positron emission tomography (PSMA-PET) detected metastatic disease in 46% of patients with high-risk prostate cancer previously classified as nonmetastatic by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback